ABSTRACT
【Objective】 To explore the safety of RhD-positive red blood cells (RBCs) immunization schedules in RhD-negative volunteers, so as to facilitate the development of domestic anti-D immunoglobulin. 【Methods】 From January 2018 to April 2020, 23 RhD negative volunteers with informed consent were enrolled and divided into initial immunization group and booster immunization group. The initial immunization included first immunization, second immunization and third immunization. Four groups, i. e. 3 cases of 20 mL, 8 of 30 mL, 6 of 40 mL, and 6 of 50 mL, were involved in initial immunization. After the initial immunization response, booster immunizations were performed every 3 months. According to the anti-D titer before each immunization, the booster immunization doses were set to 0.5, 1 and 2 mL. Whole blood samples of 5mL/ person (time) were collected 24 h and 1 week after each infusion, and the blood routine, liver, kidney and blood coagulation function and anti-D titer were detected. The differences of detection (index) values at 24 h and 1 week after the first immunization and booster immunization in each (dose) group were compared. 【Results】 No statistically significant differences were observed in hemolysis index values (all within the range of medical reference values) 24 h or 1 week after initial immunization among RhD positive RBCs of 20, 30, 40 and 50mL(P>0.05). The differences between the hemolysis index values and the basic values before the immune response (all within the range of medical reference values) after 0.5 or 1 mL booster immunizations were also not statistically different (P>0.05). However, the differences (μmol/L)between total bilirubin levels and the basic values before the immune response (1.55±1.87, 6.29±2.66) were significantly different after 2 mL booster immunization (P<0.05). 【Conclusion】 No risks affecting the safety of RhD negative volunteers was found in the immunization schedule proposed in this study.
ABSTRACT
This study set out to determine the immunomodulatory effects of a health food high-peptide meal in immunodeficient mice that was induced by either hydrocortisone (HY) or cyclophosphamide (CP). Five separate trials were performed in which animals were randomly divided into 5 groups of 12 mice for each experimental trial. Group 1 served as the vehicle control. Animals assigned to groups 3-5 (dose groups), were each administered once daily with 1.67, 3.33 or 6.67 g kg(-1) body weight of a high-peptide meal, respectively, for 30 consecutive days. Animals from groups 2 to 5 that were included in trials 1 to 4, each received an intramuscular administration of HY at 40 mg kg(-1) body weight on days 22, 24, 26, 28, 30. Animals from groups 2-5, in trial 5, each received an intraperitoneal administration of CP at 50 mg kg(-1) body weight, on days 26 and 27. On day 31, all groups of mice were differentially screened for immunomodulatory activity following the conclusion of the above experiments. In HY-treated mice, the high-peptide meal accelerated the recovery of the phagocytic function of both macrophages and the reticuloendothelial system, and restored NK cell activity. In CP-treated mice, the high-peptide meal promoted a humoral immune response to sheep red blood cells (SRBCs). These results demonstrated the immunomodulatory effects of a high-peptide meal.
